{"id":"cox2","name":"COX-2 (PTGS2)","symbol":"PTGS2","route":"/targets/cox2/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9605","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073756","uniprot":"https://www.uniprot.org/uniprotkb/P35354/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P35354","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL230","open-targets":"https://platform.opentargets.org/target/ENSG00000073756","civic":"https://civicdb.org/genes/5743/summary","oncokb":"https://www.oncokb.org/gene/PTGS2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTGS2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PTGS2","depmap":"https://depmap.org/portal/gene/PTGS2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000073756-PTGS2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5743","omim":"https://www.omim.org/entry/600262"}],"products":[{"id":"celecoxib","name":"Celecoxib","status":"approved","modality":"Oral COX-2 inhibitor","route":"/drugs/celecoxib/"}],"trials":[{"id":"metronomic-vs-cisplatin-tmh","name":"Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)","phase":"3","status":"positive"},{"id":"stampede","name":"STAMPEDE","nct":"NCT00268476","phase":"platform","status":"positive"},{"id":"nct07150949","name":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC","nct":"NCT07150949","phase":"2","status":"recruiting"},{"id":"nct07154316","name":"Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer","nct":"NCT07154316","phase":"2","status":"recruiting"},{"id":"nct05731726","name":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","nct":"NCT05731726","phase":"2","status":"recruiting"},{"id":"nct06903858","name":"Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer","nct":"NCT06903858","phase":"2","status":"recruiting"},{"id":"nct07104266","name":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","nct":"NCT07104266","phase":"2","status":"recruiting"}],"pathways":[],"companies":["pfizer"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}